KRAS inhibitor breakthroughs — the targeted therapies addressing the most frequently mutated oncogene in human cancers (present in approximately 25% of all tumors) that was considered pharmacolog...
Connexin 43 targeted therapy for oculodentodigital dysplasia — the precision medicine approach addressing the underlying GJA1 mutation disrupting gap junction intercellular communication, represe...
